New Direct-to-Consumer Prescription Delivery Channel Mitigates Risk of Medication Non-Adherence Highlighted in JAMA Internal

    New Direct-to-Consumer Prescription Delivery Channel Mitigates Risk of
     Medication Non-Adherence Highlighted in JAMA Internal Medicine Study

PR Newswire

SAN DIEGO, Feb. 27, 2013

SAN DIEGO, Feb. 27, 2013 /PRNewswire/ -- MedVantx, Inc., the company that
created the first ever controlled access to generic samples in US physician
offices, today highlighted it's MedStart Connect program as a solution to the
problem specified in a recent study published in JAMA Internal Medicine. In
the study, researchers reported that changes in pill color that often occur
during the prescription refill process significantly increase the odds of
medication non-adherence. The study suggests that consistency of appearance
from one refill to the next could alleviate issues of confusion and
non-adherence.

MedStart Connect, a new direct-to-consumer prescription delivery channel,
ensures medication appearance is consistent from the sample provided in the
physician office through the fulfillment of prescriptions through mail order
home delivery by partnering exclusively with quality manufacturers, such as
Teva Pharmaceuticals, the world's largest generic manufacturer. Patients
participating in MedStart Connect receive the same medication—same look, same
quality—every time, whether in sample form from the doctor's office or via
MedStart Connect Home Delivery.

"We have partnered with MedVantx because MedStart Connect aligns with our
commitment to enhancing patient adherence and product quality," said Maureen
Cavanaugh, Sr. Vice President, U.S. Generics Sales and Marketing, Teva
Pharmaceuticals.

As reported in JAMA Internal Medicine, formerly known as Archives of Internal
Medicine, researchers looked at refills of over 60,000 patients. Changes in
pill color from one refill to the next significantly increased the odds of
non-persistence in taking medication. 

"Our MedStart Connect Program is the only program of its kind that can ensure
patients receive medications with a consistent appearance throughout their
initial therapy and refill stages. If you can impact medication adherence in
this way, ultimately you can positively impact quality and cost of care," said
Rob Feeney, CEO, MedVantx.

About MedVantx, Inc.

MedVantx is an innovative medication management and delivery company committed
to streamlining access, reducing costs and providing helpful information to
benefit patients, physicians, health plans, employers and manufacturers. The
MedStart Connect program provides for a fully-automated, integrated,
point-of-care to consumer home delivery channel focused on increasing the
quality and cost effectiveness of the last non-managed pharmaceutical channel
– the physician office sample closet. MedStart Connect includes free initial
therapy samples of prescription and over-the-counter medication at the point
of care, a consumer helpline providing drug information, adherence management
services, and convenient consumer home delivery through its mail order
pharmacy. MedVantx has served over 3.5 million consumers through an
integrated network including health plans, manufacturers and more than 3,500
prescribers. For additional information about MedVantx visit
www.medvantx.com.

About Teva

Teva North America is a subsidiary of Teva Pharmaceuticals Ltd. In North
America, Teva has locations in 13 states, District of Columbia, Canada and
Puerto Rico and more than 9,000 employees. In fact, one in every seven
prescriptions dispensed in the U.S. is a Teva product.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), headquartered in Israel, is
a leading global pharmaceutical company, committed to providing consumers with
access to high-quality healthcare by developing, producing and marketing
affordable generic, innovative and specialty products, as well as active
pharmaceutical ingredients.

The Company is the largest maker of generic pharmaceutical products, has a
global product portfolio of more than 1,300 molecules and a direct presence in
about 60 countries. The branded businesses focus on CNS, oncology, pain,
respiratory and women's health therapeutic areas as well as biologics.

MedVantx Contact:
JD Haldeman
(858) 625-2990 ext. 130
JD.Haldeman@MedVantx.com

SOURCE MedVantx, Inc.

Website: http://www.medvantx.com